Business Description
Biodexa Pharmaceuticals PLC
ISIN : US59564R8806
Share Class Description:
BDRX: ADRTotal Employee Number:
11Description
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 139.37 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 94.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.48 | |||||
9-Day RSI | 48.72 | |||||
14-Day RSI | 46.16 | |||||
3-1 Month Momentum % | -19.84 | |||||
6-1 Month Momentum % | -71.54 | |||||
12-1 Month Momentum % | -92.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.03 | |||||
Quick Ratio | 2.03 | |||||
Cash Ratio | 1.39 | |||||
Days Payable | 69.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -0.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -60.95 | |||||
ROA % | -39.72 | |||||
ROIC % | -82.88 | |||||
3-Year ROIIC % | -4.82 | |||||
ROC (Joel Greenblatt) % | -357.99 | |||||
ROCE % | -54.54 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3827.09 | |||||
EV-to-EBIT | -12578.57 | |||||
EV-to-EBITDA | -12972.15 | |||||
EV-to-Forward-Revenue | 1.19 | |||||
EV-to-FCF | -12544.13 | |||||
Price-to-GF-Value | 1.15 | |||||
Earnings Yield (Greenblatt) % | -0.01 | |||||
FCF Yield % | -0.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BDRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biodexa Pharmaceuticals PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -143.326 | ||
| Beta | |||
| 3-Year Sharpe Ratio | -2.57 | ||
| 3-Year Sortino Ratio | -2.23 | ||
| Volatility % | 75.48 | ||
| 14-Day RSI | 46.16 | ||
| 14-Day ATR ($) | 0.294097 | ||
| 20-Day SMA ($) | 2.98961 | ||
| 12-1 Month Momentum % | -92.05 | ||
| 52-Week Range ($) | 2.4501 - 66.5 | ||
| Shares Outstanding (Mil) | 0.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biodexa Pharmaceuticals PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biodexa Pharmaceuticals PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-09-11 | In 69 days | ||
| General meeting for 2026 | 2026-06-30 10:00 | 2.85 (-1.04%) | ||
| 0.2:1 Stock Split | 2026-04-06 | 4.37 (-5.44%) | ||
| Annual report for 2025 | 2026-03-27 | 3.30 (-5.21%) | ||
| Second quarter earnings results for 2025 | 2025-09-12 | 29.65 (+5.52%) | ||
| 0.1:1 Stock Split | 2025-07-31 | 43.19 (+0.20%) | ||
| General meeting for 2025 | 2025-06-26 12:00 | 45.50 (-6.19%) | ||
| Annual report for 2024 | 2025-05-22 | 65.00 (-0.76%) | ||
| 0.04:1 Stock Split | 2024-10-04 | 300.38 (-14.18%) | ||
| Second quarter earnings results for 2024 | 2024-09-30 | 359.50 (+1.41%) |
Show
Entries
Biodexa Pharmaceuticals PLC Frequently Asked Questions
What is Biodexa Pharmaceuticals PLC(BDRX)'s stock price today?
The current price of BDRX is $2.94. The 52 week high of BDRX is $66.50 and 52 week low is $2.45.
When is next earnings date of Biodexa Pharmaceuticals PLC(BDRX)?
The next earnings date of Biodexa Pharmaceuticals PLC(BDRX) is 2026-09-11 Est..
Does Biodexa Pharmaceuticals PLC(BDRX) pay dividends? If so, how much?
Biodexa Pharmaceuticals PLC(BDRX) does not pay dividend.
Guru Commentaries on NAS:BDRX
No articles.
Press Release
Articles on Biodexa Pharmaceuticals PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers